Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.04 USD | +0.33% | -7.38% | -39.44% |
Sales 2024 * | 5.3M 6.75M | Sales 2025 * | 75.71M 96.43M | Capitalization | 766M 975M |
---|---|---|---|---|---|
Net income 2024 * | -104M -132M | Net income 2025 * | -65M -82.78M | EV / Sales 2024 * | 110 x |
Net cash position 2024 * | 184M 234M | Net cash position 2025 * | 146M 186M | EV / Sales 2025 * | 8.18 x |
P/E ratio 2024 * |
-12.7
x | P/E ratio 2025 * |
-30.4
x | Employees | 79 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 75.42% |
Latest transcript on Verona Pharma plc
1 day | +0.33% | ||
1 week | -7.38% | ||
Current month | -22.07% | ||
1 month | -21.00% | ||
3 months | -26.99% | ||
6 months | -15.45% | ||
Current year | -39.44% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 59 | 20-01-31 | |
Mark Hahn
DFI | Director of Finance/CFO | 61 | 20-02-29 |
Kavita Aggarwal
CTO | Chief Tech/Sci/R&D Officer | - | 22-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mahendra Shah
BRD | Director/Board Member | 79 | 16-06-16 |
Vikas Sinha
BRD | Director/Board Member | 60 | 16-09-11 |
David Ebsworth
CHM | Chairman | 69 | 14-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.09% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-24 | 12.04 | +0.33% | 419,884 |
24-05-23 | 12 | -4.76% | 834,685 |
24-05-22 | 12.6 | +0.80% | 784,488 |
24-05-21 | 12.5 | -2.19% | 754,544 |
24-05-20 | 12.78 | -1.69% | 630,196 |
Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-39.44% | 976M | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.69% | 21.78B | |
-10.60% | 18.09B | |
-41.25% | 16.72B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- VRNA Stock